TABLE 2.
Absolute change from baseline to Week 2 in lipoprotein particle concentrations (nmol/L) for the placebo and ANA 150 mg groups as measured by IM methodology
| Placebo (N=10) | ANA 150 mg (N=10) | Differences in LS mean change from baseline(95% CI)aPlacebo vs.ANA 150 mg | |||
| Lipoprotein size fractions | Mean baseline (SE) | Mean Week 2 (SE) | Mean baseline (SE) | Mean Week 2 (SE) | |
| Total VLDL | 156.51 (5.89) | 147.45 (15.82) | 154.57 (13.71) | 101.80 (6.93) | −44.95 (−74.43, −15.46)c |
| Largeb | 25.94 (15.59) | 21.24 (17.67) | 28.36 (10.15) | 18.64(6.36) | −6.86 (−13.68, −0.66) |
| Medium | 65.18 (3.86) | 60.58 (6.86) | 66.14 (6.45) | 42.66 (3.46) | −18.31 (−30.93, −5.70)c |
| Small | 66.55 (2.87) | 63.12 (7.24) | 61.40 (5.20) | 39.67 (3.18) | −21.95 (−35.82, −8.08)c |
| Total IDL | 365.05 (18.13) | 327.55 (36.81) | 303.94 (27.32) | 260.10 (22.15) | −58.49 (−151.2, 34.22) |
| Large | 155.69 (6.89) | 146.53 (19.23) | 142.25 (13.02) | 83.22 (7.22) | −60.87 (−96.59, -25.15)c |
| Small | 209.37 (20.52) | 181.02 (20.66) | 161.69 (16.89) | 176.88 (16.18) | 6.88 (−58.94, 72.69) |
| Total LDL | 1355.3 (82.00) | 1227.5 (158.17) | 1254.0 (84.39) | 767.10 (38.74) | −419.3 (−682.0, −156.6)c |
| Large 1b | 346.07 (179.07) | 226.94 (134.86) | 254.60 (188.69) | 149.80 (41.29) | −75.84 (−189.9, 50.57) |
| Medium 2ab | 229.05 (103.64) | 208.15 (92.56) | 255.64 (190.67) | 99.79 (11.48) | −126.4 (−192.2, −31.25)c |
| Medium 2bb | 297.33 (187.92) | 243.02 (155.97) | 307.32 (94.16) | 134.82 (17.17) | −126.3 (−204.0, −52.12)c |
| Small 3a | 266.41 (59.76) | 276.43 (76.87) | 227.02 (35.13) | 121.42 (5.99) | −127.8 (−223.1, −32.55)c |
| Small 3bb | 41.58 (38.60) | 40.07 (110.02) | 41.41 (26.15) | 49.05 (15.21) | 6.79 (−41.49, 33.02) |
| Very small 4a | 63.38 (6.13) | 64.35 (10.59) | 52.60 (3.48) | 84.81 (5.11) | 28.23 (2.12, 54.34) |
| Very small 4b | 84.98 (9.52) | 73.48 (8.85) | 67.07 (6.66) | 117.09 (7.17) | 57.52 (32.38, 82.66)c |
| Total HDL | 5769.8 (355.82) | 4785.7 (362.07) | 4589.3 (558.16) | 7658.7 (595.16) | 3364.6 (1994.8, 4734.4)c,d |
| Large 2b | 1346.9 (223.29) | 997.01 (159.35) | 738.57 (108.85) | 3382.2 (348.97) | 2851.9 (2056.7, 3647.2)c,d |
| Smaller 2a+3b | 4403.2 (2184.1) | 3806.4 (1101.2) | 3509.3 (956.80) | 4051.3 (1078.4) | 1254.8 (−610.7, 2197.2) |
a
Least squares mean and 95% confidence interval from ANCOVA model with treatment as a factor and baseline lipid level as a covariate.
b
Change from baseline data not normally distributed; Hodges-Lehman estimate of median and distribution free confidence interval presented; median (IQR) presented at baseline and Week 2.
c
Significant with false discovery rate less than 5%
d
Significant dose-response with adjustment for false discovery rate less than 5%. Testing performed in step-down fashion.
CI, confidence interval; IDL, intermediate density lipoprotein; IM, ion mobility; IQR, interquartile range.